BriaCell Therapeutics Corp. Warrant (BCTXZ)

CA — Healthcare Sector
Peers: NKGN  NCEL  XRTX  ELAB  WINT  VRAX  AIMD  DRMA  ATXI  MLEC 

Automate Your Wheel Strategy on BCTXZ

With Tiblio's Option Bot, you can configure your own wheel strategy including BCTXZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BCTXZ
  • Rev/Share 0.0
  • Book/Share 1.5722
  • PB 0.2036
  • Debt/Equity 0.0
  • CurrentRatio 5.0092
  • ROIC 0.0

 

  • MktCap 2168856.0
  • FreeCF/Share -2.5551
  • PFCF -0.077
  • PE -0.1341
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -2.8145

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About BriaCell Therapeutics Corp. Warrant (BCTXZ)

  • IPO Date 2025-04-25
  • Website https://www.briacell.com
  • Industry Biotechnology
  • CEO William V. Williams FCPA,
  • Employees 16
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.